4.3 Article

CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?

Journal

OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
Volume 21, Issue 9, Pages 509-519

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/omi.2017.0101

Keywords

drug metabolism variation; global personalized medicine; developing world omics; biomarkers; systems diagnostics

Funding

  1. CONACYT-Mexico [2009-01-113063]
  2. AEXCID of Junta de Extremadura
  3. ISCIII [CD13/00348-FdA]

Ask authors/readers for more resources

Global precision medicine demands characterization of drug metabolism and phenotype variation in diverse populations, including the indigenous societies. Arelated question is the extent towhich CYP450 drugmetabolizing enzyme genotype and phenotype data are concordant and whether they can be used interchangeably. These issues are increasingly debated as precision medicine continues to expand as a popular research topic worldwide. We report here the first study in clinically relevant CYP450 drug metabolism phenotypes and genotypes in Mexican Amerindian indigenous subjects. In a large sample of 450 unrelated and medication free Mexican Amerindian indigenous healthy persons from four Mexican states (Chihuahua, Durango, Nayarit, and Sonora), we performed multiplexed phenotyping for the CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 drug metabolizing enzymes using the CEIBA cocktail and genotyped the same pathways for functional polymorphic variation. Remarkable interindividual variability was found for the actual drug metabolizing capacity of all the enzymes analyzed, and, more specifically, the metabolic ratios calculated were significantly different across individuals with different number of active alleles for CYP2C9, CYP2C19, and CYP2D6. The drug metabolizing capacity predicted'' from the genotype determined was not in accordance with the actual capacity measured'' by phenotyping in several individuals for CYP2C9, CYP2C19, and CYP2D6. Consequently, a more extensive genotyping of the main CYP enzymes, including rare variants, together with the analysis of the actual drug metabolizing capacity using an appropriate phenotyping approach will add valuable information for accurate drug metabolism studies, especially useful in understudied populations such as Mexican Amerindians. In sum, this study demonstrates that current personalized medicine strategies based on predicted'' phenotype from genotyping of alleles with high frequency in European populations are not adequate for Mestizos and Native American populations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available